Moderna shares are trading higher after the company announced that MRNA-1283 met the primary endpoints in its Phase 3 clinical trial. Additionally, Blackstone Life Sciences announced it will invest up to $750 million to support Moderna's influenza program. The company will host an investor event today.
Portfolio Pulse from Benzinga Newsdesk
Moderna's stock is up following the announcement that MRNA-1283 met its Phase 3 trial primary endpoints. Blackstone Life Sciences will invest up to $750 million in Moderna's flu program, with an investor event scheduled today.
March 27, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's MRNA-1283 meets Phase 3 trial endpoints, and Blackstone Life Sciences invests $750 million in its flu program, boosting investor confidence.
The positive outcome of the Phase 3 trial for MRNA-1283 and the substantial investment from Blackstone Life Sciences are significant indicators of Moderna's potential for future growth, particularly in its influenza program. These developments are likely to increase investor confidence and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100